董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Michael Kaseta | 男 | Director | 49 | 未披露 | 未持股 | 2025-10-27 |
| Adam Morgan | 男 | Chairman of the Board | 46 | 未披露 | 未持股 | 2025-10-27 |
| Craig Collard | 男 | Chief Executive Officer and Director | 59 | 未披露 | 未持股 | 2025-10-27 |
| Sharmila Dissanaike | 女 | Director | 50 | 28.53万美元 | 未持股 | 2025-10-27 |
| Thomas Cusack | 男 | Director | -- | 未披露 | 未持股 | 2025-10-27 |
| Craig A. Johnson | 男 | Director | 63 | 33.92万美元 | 未持股 | 2025-10-27 |
| Christian Waage | 男 | Director | 58 | 30.92万美元 | 未持股 | 2025-10-27 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| William Forbes | 男 | Executive Vice President, Chief Development Officer | 63 | 未披露 | 未持股 | 2025-10-27 |
| Craig Collard | 男 | Chief Executive Officer and Director | 59 | 未披露 | 未持股 | 2025-10-27 |
| Ira Duarte | 女 | Executive Vice President, Chief Financial Officer | 56 | 未披露 | 未持股 | 2025-10-27 |
| Mark Hensley | 男 | Executive Vice President, Chief Operating Officer | 42 | 未披露 | 未持股 | 2025-10-27 |
董事简历
中英对照 | 中文 | 英文- Michael Kaseta
-
Michael Kaseta，自2023年3月起担任董事会成员。Kaseta先生自2020年11月起担任Liquidia Corporation首席财务官。Kaseta先生于2019年1月至2020年11月担任Aerami Therapeutics，Inc.的首席财务官，该公司是一家私营生物技术公司，专注于开发治疗严重呼吸系统疾病（包括肺动脉高压）的改良疗法，并于2018年3月开始担任前专业制药公司（“Aralez”）Aralez制药公司的首席财务官。Aralez于2018年8月申请破产保护，Kaseta先生一直担任Aralez的首席财务官，直到2019年1月离职。Kaseta先生曾于2017年11月至2018年3月担任Aralez的财务主管兼临时首席财务官，并于2016年9月至2017年11月担任公司财务总监。在加入Aralez之前，Kaseta先生曾在专注于人类健康的全球生物制药公司赛诺菲 S.A.担任多个职位，包括2015年4月至2016年9月担任赛诺菲北美全球服务部首席财务官。Kaseta先生曾于2013年1月至2015年4月担任赛诺菲北美制药控制副总裁，于2007年3月至2013年12月担任赛诺菲财务共享服务副总裁，并于2005年至2007年担任技术会计总监。Kaseta先生拥有詹姆斯麦迪逊大学会计学学士学位，是新泽西州的注册会计师（非在职）。
Michael Kaseta,has been a member of the Board since March 2023. Mr. Kaseta has served as Chief Financial Officer of Liquidia Corporation since November 2020. Mr. Kaseta served as Chief Financial Officer of Aerami Therapeutics, Inc., a privately held biotech company focused on the development of improved therapies for the treatment of severe respiratory diseases, including pulmonary arterial hypertension, from January 2019 until November 2020, and served as Chief Financial Officer of Aralez Pharmaceuticals Inc., a former specialty pharmaceutical company ("Aralez"), beginning in March 2018. Aralez filed for bankruptcy protection in August 2018, and Mr. Kaseta remained Chief Financial Officer of Aralez until his departure in January 2019. Mr. Kaseta previously served as Head of Finance and Interim Chief Financial Officer of Aralez from November 2017 until March 2018 and Corporate Controller from September 2016 until November 2017. Prior to joining Aralez, Mr. Kaseta held various positions at Sanofi S.A., a global biopharmaceutical company focused on human health, including most recently Chief Financial Officer Sanofi North America, Global Services, from April 2015 through September 2016. Mr. Kaseta was previously the Vice President Sanofi NA Pharma Controlling from January 2013 through April 2015, Vice President, Sanofi Financial Shared Services from March 2007 through December 2013 and Director of Technical Accounting from 2005 to 2007. Mr. Kaseta holds a BBA in accounting from James Madison University and is a CPA (inactive) licensed in the state of New Jersey. - Michael Kaseta，自2023年3月起担任董事会成员。Kaseta先生自2020年11月起担任Liquidia Corporation首席财务官。Kaseta先生于2019年1月至2020年11月担任Aerami Therapeutics，Inc.的首席财务官，该公司是一家私营生物技术公司，专注于开发治疗严重呼吸系统疾病（包括肺动脉高压）的改良疗法，并于2018年3月开始担任前专业制药公司（“Aralez”）Aralez制药公司的首席财务官。Aralez于2018年8月申请破产保护，Kaseta先生一直担任Aralez的首席财务官，直到2019年1月离职。Kaseta先生曾于2017年11月至2018年3月担任Aralez的财务主管兼临时首席财务官，并于2016年9月至2017年11月担任公司财务总监。在加入Aralez之前，Kaseta先生曾在专注于人类健康的全球生物制药公司赛诺菲 S.A.担任多个职位，包括2015年4月至2016年9月担任赛诺菲北美全球服务部首席财务官。Kaseta先生曾于2013年1月至2015年4月担任赛诺菲北美制药控制副总裁，于2007年3月至2013年12月担任赛诺菲财务共享服务副总裁，并于2005年至2007年担任技术会计总监。Kaseta先生拥有詹姆斯麦迪逊大学会计学学士学位，是新泽西州的注册会计师（非在职）。
- Michael Kaseta,has been a member of the Board since March 2023. Mr. Kaseta has served as Chief Financial Officer of Liquidia Corporation since November 2020. Mr. Kaseta served as Chief Financial Officer of Aerami Therapeutics, Inc., a privately held biotech company focused on the development of improved therapies for the treatment of severe respiratory diseases, including pulmonary arterial hypertension, from January 2019 until November 2020, and served as Chief Financial Officer of Aralez Pharmaceuticals Inc., a former specialty pharmaceutical company ("Aralez"), beginning in March 2018. Aralez filed for bankruptcy protection in August 2018, and Mr. Kaseta remained Chief Financial Officer of Aralez until his departure in January 2019. Mr. Kaseta previously served as Head of Finance and Interim Chief Financial Officer of Aralez from November 2017 until March 2018 and Corporate Controller from September 2016 until November 2017. Prior to joining Aralez, Mr. Kaseta held various positions at Sanofi S.A., a global biopharmaceutical company focused on human health, including most recently Chief Financial Officer Sanofi North America, Global Services, from April 2015 through September 2016. Mr. Kaseta was previously the Vice President Sanofi NA Pharma Controlling from January 2013 through April 2015, Vice President, Sanofi Financial Shared Services from March 2007 through December 2013 and Director of Technical Accounting from 2005 to 2007. Mr. Kaseta holds a BBA in accounting from James Madison University and is a CPA (inactive) licensed in the state of New Jersey.
- Adam Morgan
-
Adam Morgan，自2023年3月起担任董事会成员。自2020年7月以来，摩根一直担任Velan Capital Investment Management LP的首席投资官，该公司是一家专注于医疗保健的投资公司，总部位于乔治亚州阿尔法利塔。摩根先生目前还担任Heron Therapeutics, Inc.（纳斯达克股票代码：HRTX）的董事会成员，该公司是一家上市生物技术公司，专注于提高急性和肿瘤患者的护理标准，自2023年2月起，他还担任该公司董事会主席和公司提名和公司治理委员会成员，以及健康展望公司，这是一家位于纽约州的预测性医疗保健技术和服务的私人开发商，自2023年1月起，他还担任公司审计委员会主席。此前，摩根曾于2018年2月至2020年6月担任Broadfin Capital，LLC高级分析师，这是一家专注于医疗保健的投资公司，总部位于纽约州纽约市，负责生物技术和制药行业。在此之前，摩根曾在Iguana Healthcare Partners LLC担任高级分析师，该公司是一家专注于医疗保健的投资公司，总部位于纽约州纽约市，2015年至2018年1月，他在该公司负责医疗器械和专业制药业务。摩根还曾在Pura Vida Investments，LLC担任分析师，这是一家专注于医疗保健的投资公司，2014年至2015年，他在该公司负责全球医疗器械业务。在其职业生涯的早期，摩根先生于2014年1月至2014年6月在金融服务公司高宏集团公司（Cowen Inc.的子公司）担任医疗用品和设备团队的研究助理。摩根先生在明尼苏达大学获得化学理学士学位，在明尼苏达大学卡尔森管理学院获得MBA学位。
Adam Morgan,has served as a director of Heron since February 2023 and as Chairman of the Board since April 2023. Mr. Morgan has served as the Chief Investment Officer of Velan Capital Investment Management LP, a healthcare-dedicated investment firm based in Alpharetta, Georgia, since July 2020. Mr. Morgan has also served on the board of directors of Health Outlook Corporation, a privately-held developer of predictive healthcare technology and service based in New York, New York, where he serves as chair of the company's audit committee, since January 2023. Previously, Mr. Morgan served on the board of directors of Alimera Sciences, Inc. (formerly NASDAQ: ALIM), a biopharmaceutical company, from March 2023 until its merger with ANI Pharmaceuticals, Inc. in September 2024. Prior to that, Mr. Morgan served as Senior Analyst at Broadfin Capital, LLC, a healthcare dedicated investment firm based in New York, New York, where he covered the Biotech and Pharmaceutical sectors, from 2018 to June 2020, and as Senior Analyst at Iguana Healthcare Partners LLC, a healthcare-dedicated investment firm based in New York, New York, where he covered Medical Devices and Specialty Pharmaceuticals, from 2015 to 2018. Mr. Morgan also served as an Analyst at Pura Vida Investments, LLC, a healthcare-focused investment firm, where he covered global Medical Devices, from 2014 to 2015. Earlier in his career, Mr. Morgan served as a Research Associate at Cowen and Company (a subsidiary of Cowen Inc.), a financial services company, on the firm's Medical Supplies and Devices team, in 2014. Mr. Morgan received his B.S. degree in chemistry from the University of Minnesota and his M.B.A. degree from the Carlson School of Management at the University of Minnesota. - Adam Morgan，自2023年3月起担任董事会成员。自2020年7月以来，摩根一直担任Velan Capital Investment Management LP的首席投资官，该公司是一家专注于医疗保健的投资公司，总部位于乔治亚州阿尔法利塔。摩根先生目前还担任Heron Therapeutics, Inc.（纳斯达克股票代码：HRTX）的董事会成员，该公司是一家上市生物技术公司，专注于提高急性和肿瘤患者的护理标准，自2023年2月起，他还担任该公司董事会主席和公司提名和公司治理委员会成员，以及健康展望公司，这是一家位于纽约州的预测性医疗保健技术和服务的私人开发商，自2023年1月起，他还担任公司审计委员会主席。此前，摩根曾于2018年2月至2020年6月担任Broadfin Capital，LLC高级分析师，这是一家专注于医疗保健的投资公司，总部位于纽约州纽约市，负责生物技术和制药行业。在此之前，摩根曾在Iguana Healthcare Partners LLC担任高级分析师，该公司是一家专注于医疗保健的投资公司，总部位于纽约州纽约市，2015年至2018年1月，他在该公司负责医疗器械和专业制药业务。摩根还曾在Pura Vida Investments，LLC担任分析师，这是一家专注于医疗保健的投资公司，2014年至2015年，他在该公司负责全球医疗器械业务。在其职业生涯的早期，摩根先生于2014年1月至2014年6月在金融服务公司高宏集团公司（Cowen Inc.的子公司）担任医疗用品和设备团队的研究助理。摩根先生在明尼苏达大学获得化学理学士学位，在明尼苏达大学卡尔森管理学院获得MBA学位。
- Adam Morgan,has served as a director of Heron since February 2023 and as Chairman of the Board since April 2023. Mr. Morgan has served as the Chief Investment Officer of Velan Capital Investment Management LP, a healthcare-dedicated investment firm based in Alpharetta, Georgia, since July 2020. Mr. Morgan has also served on the board of directors of Health Outlook Corporation, a privately-held developer of predictive healthcare technology and service based in New York, New York, where he serves as chair of the company's audit committee, since January 2023. Previously, Mr. Morgan served on the board of directors of Alimera Sciences, Inc. (formerly NASDAQ: ALIM), a biopharmaceutical company, from March 2023 until its merger with ANI Pharmaceuticals, Inc. in September 2024. Prior to that, Mr. Morgan served as Senior Analyst at Broadfin Capital, LLC, a healthcare dedicated investment firm based in New York, New York, where he covered the Biotech and Pharmaceutical sectors, from 2018 to June 2020, and as Senior Analyst at Iguana Healthcare Partners LLC, a healthcare-dedicated investment firm based in New York, New York, where he covered Medical Devices and Specialty Pharmaceuticals, from 2015 to 2018. Mr. Morgan also served as an Analyst at Pura Vida Investments, LLC, a healthcare-focused investment firm, where he covered global Medical Devices, from 2014 to 2015. Earlier in his career, Mr. Morgan served as a Research Associate at Cowen and Company (a subsidiary of Cowen Inc.), a financial services company, on the firm's Medical Supplies and Devices team, in 2014. Mr. Morgan received his B.S. degree in chemistry from the University of Minnesota and his M.B.A. degree from the Carlson School of Management at the University of Minnesota.
- Craig Collard
-
Craig Collard，自2023年2月起担任Heron董事，自2023年4月起担任首席执行官。Collard先生最近担任Veloxis Pharmaceutics A/S（现为Veloxis Pharmaceuticals Inc.，“Veloxis”）的首席执行官，之后该公司于2015年至2021年12月被Asahi Kasei Corp收购，该公司是一家专注于移植的制药公司，其主要办事处位于北卡罗来纳州卡里，并继续留在Veloxis的顾问委员会中。在加入Veloxis之前，Collard先生曾于2011年担任制药公司科纳斯通医疗公司（“Cornerstone”）的首席执行官和董事会主席，直到该公司于2014年被Chiesi Farmaceutici S.P.A.收购。Collard先生还曾于2010年至2011年担任Cornerstone的临时首席财务官，并于2008年至2011年担任其总裁。Collard先生曾于2004年至2008年担任制药公司Cornerstone BioPharma Inc.（前身为Cornerstone BioPharma Holdings，Ltd.）的创始人、总裁兼首席执行官，并担任其董事会成员。在此之前，Collard先生曾担任Carolina Pharmaceuticals，Inc.的总裁兼首席执行官，这是一家他于2003年创立的专业制药公司。Collard先生目前担任TerrAscend Corp.的董事会成员，该公司是一家位于加拿大密西沙加的北美大麻运营商，自2018年12月起任职。Collard先生此前曾于2020年5月至2022年7月担任Sierra Oncology, Inc.的董事会成员，该公司是一家总部位于加利福尼亚州圣马特奥的后期生物制药公司，被葛兰素史克公司收购。他还担任Opiant Pharmaceuticals, Inc.的董事长，该公司是加利福尼亚州圣莫尼卡的一家专业制药公司，开发治疗物质和Heron Therapeutics的疗法，自2018年10月以来，该公司一直在开发治疗疾病和药物过量的疗法，直到2023年3月1日被Indivior收购。Collard先生拥有南方理工学院（现为南方理工大学州立大学）的工学学士学位。Collard先生最初是根据公司与Rubric Capital Management LP及其某些关联公司和Velan Capital Investment Management LP及其某些关联公司于2023年2月21日就董事会组成和其他相关事项的变更（“合作协议”）签订的合作协议（“合作协议”）被任命为董事。
Craig Collard,has served as a director of Heron since February 2023 and as Chief Executive Officer since April 2023. Mr. Collard most recently served as the Chief Executive Officer of Veloxis Pharmaceutics A/S (now Veloxis Pharmaceuticals Inc., "Veloxis") before it was acquired by Asahi Kasei Corp, a transplant focused pharmaceutical company with its principal office in Cary, North Carolina, from 2015 to December 2021. Prior to joining Veloxis, Mr. Collard served as the Chief Executive Officer and the Chairman of the Board of Directors of Cornerstone Therapeutics, Inc., a pharmaceutical company ("Cornerstone"), from 2011 until it was acquired by Chiesi Farmaceutici S.p.A. ("Chiesi") in 2014. Mr. Collard also served as Cornerstone's Interim Chief Financial Officer, from 2010 to 2011, and as its President, from 2008 to 2011. Mr. Collard served as the Founder, President and Chief Executive Officer of Cornerstone BioPharma Inc. (formerly Cornerstone BioPharma Holdings, Ltd.), a pharmaceutical company, and as a member of its board of directors, from 2004 to 2008. Prior to that, Mr. Collard served as President and Chief Executive Officer of Carolina Pharmaceuticals, Inc., a specialty pharmaceutical company that he founded in 2003. Mr. Collard has served on the board of directors of TerrAscend Corp. (TSX: TSND), a North American cannabis operator based in Mississauga, Canada ("TerrAscend"), since December 2018. Mr. Collard previously served as a member of the board of directors of Sierra Oncology, Inc., a San Mateo, California-based late-stage biopharmaceutical company acquired by GlaxoSmithKline plc, from May 2020 to July 2022. He also served as Chairman of Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company in Santa Monica, California developing therapies to treat substance and Heron Therapeutics, Inc. e disorders and drug overdose since October 2018 until it was acquired by Indivior on March 1, 2023. Mr. Collard holds a B.S. degree in engineering from the Southern College of Technology (now Southern Polytechnic State University). Mr. Collard was initially appointed as a director of the Company pursuant to a Cooperation Agreement, dated as of February 21, 2023 (the ''Cooperation Agreement"), by and between the Company, Rubric Capital Management LP and certain of its affiliates and Velan Capital Investment Management LP and certain of its affiliates, regarding changes to the composition of the Board and other related matters. - Craig Collard，自2023年2月起担任Heron董事，自2023年4月起担任首席执行官。Collard先生最近担任Veloxis Pharmaceutics A/S（现为Veloxis Pharmaceuticals Inc.，“Veloxis”）的首席执行官，之后该公司于2015年至2021年12月被Asahi Kasei Corp收购，该公司是一家专注于移植的制药公司，其主要办事处位于北卡罗来纳州卡里，并继续留在Veloxis的顾问委员会中。在加入Veloxis之前，Collard先生曾于2011年担任制药公司科纳斯通医疗公司（“Cornerstone”）的首席执行官和董事会主席，直到该公司于2014年被Chiesi Farmaceutici S.P.A.收购。Collard先生还曾于2010年至2011年担任Cornerstone的临时首席财务官，并于2008年至2011年担任其总裁。Collard先生曾于2004年至2008年担任制药公司Cornerstone BioPharma Inc.（前身为Cornerstone BioPharma Holdings，Ltd.）的创始人、总裁兼首席执行官，并担任其董事会成员。在此之前，Collard先生曾担任Carolina Pharmaceuticals，Inc.的总裁兼首席执行官，这是一家他于2003年创立的专业制药公司。Collard先生目前担任TerrAscend Corp.的董事会成员，该公司是一家位于加拿大密西沙加的北美大麻运营商，自2018年12月起任职。Collard先生此前曾于2020年5月至2022年7月担任Sierra Oncology, Inc.的董事会成员，该公司是一家总部位于加利福尼亚州圣马特奥的后期生物制药公司，被葛兰素史克公司收购。他还担任Opiant Pharmaceuticals, Inc.的董事长，该公司是加利福尼亚州圣莫尼卡的一家专业制药公司，开发治疗物质和Heron Therapeutics的疗法，自2018年10月以来，该公司一直在开发治疗疾病和药物过量的疗法，直到2023年3月1日被Indivior收购。Collard先生拥有南方理工学院（现为南方理工大学州立大学）的工学学士学位。Collard先生最初是根据公司与Rubric Capital Management LP及其某些关联公司和Velan Capital Investment Management LP及其某些关联公司于2023年2月21日就董事会组成和其他相关事项的变更（“合作协议”）签订的合作协议（“合作协议”）被任命为董事。
- Craig Collard,has served as a director of Heron since February 2023 and as Chief Executive Officer since April 2023. Mr. Collard most recently served as the Chief Executive Officer of Veloxis Pharmaceutics A/S (now Veloxis Pharmaceuticals Inc., "Veloxis") before it was acquired by Asahi Kasei Corp, a transplant focused pharmaceutical company with its principal office in Cary, North Carolina, from 2015 to December 2021. Prior to joining Veloxis, Mr. Collard served as the Chief Executive Officer and the Chairman of the Board of Directors of Cornerstone Therapeutics, Inc., a pharmaceutical company ("Cornerstone"), from 2011 until it was acquired by Chiesi Farmaceutici S.p.A. ("Chiesi") in 2014. Mr. Collard also served as Cornerstone's Interim Chief Financial Officer, from 2010 to 2011, and as its President, from 2008 to 2011. Mr. Collard served as the Founder, President and Chief Executive Officer of Cornerstone BioPharma Inc. (formerly Cornerstone BioPharma Holdings, Ltd.), a pharmaceutical company, and as a member of its board of directors, from 2004 to 2008. Prior to that, Mr. Collard served as President and Chief Executive Officer of Carolina Pharmaceuticals, Inc., a specialty pharmaceutical company that he founded in 2003. Mr. Collard has served on the board of directors of TerrAscend Corp. (TSX: TSND), a North American cannabis operator based in Mississauga, Canada ("TerrAscend"), since December 2018. Mr. Collard previously served as a member of the board of directors of Sierra Oncology, Inc., a San Mateo, California-based late-stage biopharmaceutical company acquired by GlaxoSmithKline plc, from May 2020 to July 2022. He also served as Chairman of Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company in Santa Monica, California developing therapies to treat substance and Heron Therapeutics, Inc. e disorders and drug overdose since October 2018 until it was acquired by Indivior on March 1, 2023. Mr. Collard holds a B.S. degree in engineering from the Southern College of Technology (now Southern Polytechnic State University). Mr. Collard was initially appointed as a director of the Company pursuant to a Cooperation Agreement, dated as of February 21, 2023 (the ''Cooperation Agreement"), by and between the Company, Rubric Capital Management LP and certain of its affiliates and Velan Capital Investment Management LP and certain of its affiliates, regarding changes to the composition of the Board and other related matters.
- Sharmila Dissanaike
-
Sharmila Dissanaike，自2021年起担任Heron的董事。Dissanaike博士自2016年起担任得克萨斯理工大学Health Sciences中心（TTUHSC）大学特聘教授和外科Peter C. Canizaro主席。此外，从2015年到2018年，Dissanaike博士担任德克萨斯州拉伯克市大学医学中心（UMC）Timothy J. Harnar烧伤中心的临时主任。从2014年到2017年，Dissanaike博士担任UMC John A. Griswold一级创伤中心的创伤医疗主任。2021年1月，她被州长格雷格·阿博特任命为德克萨斯州医疗委员会成员。Dissanaike博士是一位临床活跃的创伤、烧伤和急性护理外科医生，在她的职业生涯中，她获得了50多个临床、学术和研究卓越和服务奖项。Dissanaike博士发表了100多篇同行评审的科学文章，此外还有众多书籍章节、同行评审的演讲以及国家和国际特邀讲座。Dissanaike博士担任多个国家领导和质量保证职务，包括美国烧伤协会验证委员会主席、美国外科医生学会创伤验证委员会和创伤委员会成员，以及美国烧伤协会和西南外科大会的董事会成员。她在美国外科医生学院担任州长，并在伦理委员会、农村外科咨询委员会和项目委员会任职，突出了她广泛的兴趣和长期致力于推进手术护理的各个方面。Dissanaike博士在澳大利亚悉尼大学获得医学学位，在斯里兰卡科伦坡的卫理公会学院获得本科学位。Dissanaike博士完成了她在华盛顿大学港湾医学中心、TTUHSC外科、贝斯以色列医学中心阿尔伯特·爱因斯坦医学院外科和inverclyde医院医学科、National Health服务的研究生医学培训。
Sharmila Dissanaike,has served as a director of Heron since September 2021. Dr. Dissanaike is currently the Chair of Surgery at the University of New Mexico, Albuquerque, NM. Dr. Dissanaike was previously University Distinguished Professor and Peter C. Canizaro Chair of the Department of Surgery at Texas Tech University Health Sciences Center ("TTUHSC") since 2016. In addition, from 2015 to 2018, Dr. Dissanaike served as Interim Director of the Timothy J. Harnar Burn Center at University Medical Center in Lubbock, Texas ("UMC"). From 2014 to 2017, Dr. Dissanaike served as Trauma Medical Director of the John A. Griswold Level 1 Trauma Center at UMC. In January 2021, she was appointed to the Texas Medical Board by Governor Greg Abbott. Dr. Dissanaike is a clinically active trauma, burn and acute care surgeon who has won over 50 awards for clinical, academic and research excellence and service during her career. Dr. Dissanaike has published over 100 peer-reviewed scientific articles, in addition to numerous book chapters, peer-reviewed presentations and national and international invited lectureships. Dr. Dissanaike holds multiple national leadership and quality assurance roles including Chair of the American Burn Association Verification Committee, member of the American College of Surgeons Trauma Verification Committee and Committee on Trauma, and Board member of each of the American Burn Association and Southwestern Surgical Congress. She serves the American College of Surgeons as Governor and on the Committee for Ethics, the Advisory Council of Rural Surgery and Program Committee, highlighting her wide array of interests and longstanding dedication to advancing all aspects of surgical care. Dr. Dissanaike received her medical degree from the University of Sydney, Australia and her undergraduate degree from Methodist College in Colombo, Sri Lanka. Dr. Dissanaike completed her postgraduate medical training at the University of Washington at Harborview Medical Center, the Department of Surgery at TTUHSC, the Department of Surgery at Albert Einstein College of Medicine at Beth Israel Medical Center and the Department of Medicine at Inverclyde Hospital, National Health Service. - Sharmila Dissanaike，自2021年起担任Heron的董事。Dissanaike博士自2016年起担任得克萨斯理工大学Health Sciences中心（TTUHSC）大学特聘教授和外科Peter C. Canizaro主席。此外，从2015年到2018年，Dissanaike博士担任德克萨斯州拉伯克市大学医学中心（UMC）Timothy J. Harnar烧伤中心的临时主任。从2014年到2017年，Dissanaike博士担任UMC John A. Griswold一级创伤中心的创伤医疗主任。2021年1月，她被州长格雷格·阿博特任命为德克萨斯州医疗委员会成员。Dissanaike博士是一位临床活跃的创伤、烧伤和急性护理外科医生，在她的职业生涯中，她获得了50多个临床、学术和研究卓越和服务奖项。Dissanaike博士发表了100多篇同行评审的科学文章，此外还有众多书籍章节、同行评审的演讲以及国家和国际特邀讲座。Dissanaike博士担任多个国家领导和质量保证职务，包括美国烧伤协会验证委员会主席、美国外科医生学会创伤验证委员会和创伤委员会成员，以及美国烧伤协会和西南外科大会的董事会成员。她在美国外科医生学院担任州长，并在伦理委员会、农村外科咨询委员会和项目委员会任职，突出了她广泛的兴趣和长期致力于推进手术护理的各个方面。Dissanaike博士在澳大利亚悉尼大学获得医学学位，在斯里兰卡科伦坡的卫理公会学院获得本科学位。Dissanaike博士完成了她在华盛顿大学港湾医学中心、TTUHSC外科、贝斯以色列医学中心阿尔伯特·爱因斯坦医学院外科和inverclyde医院医学科、National Health服务的研究生医学培训。
- Sharmila Dissanaike,has served as a director of Heron since September 2021. Dr. Dissanaike is currently the Chair of Surgery at the University of New Mexico, Albuquerque, NM. Dr. Dissanaike was previously University Distinguished Professor and Peter C. Canizaro Chair of the Department of Surgery at Texas Tech University Health Sciences Center ("TTUHSC") since 2016. In addition, from 2015 to 2018, Dr. Dissanaike served as Interim Director of the Timothy J. Harnar Burn Center at University Medical Center in Lubbock, Texas ("UMC"). From 2014 to 2017, Dr. Dissanaike served as Trauma Medical Director of the John A. Griswold Level 1 Trauma Center at UMC. In January 2021, she was appointed to the Texas Medical Board by Governor Greg Abbott. Dr. Dissanaike is a clinically active trauma, burn and acute care surgeon who has won over 50 awards for clinical, academic and research excellence and service during her career. Dr. Dissanaike has published over 100 peer-reviewed scientific articles, in addition to numerous book chapters, peer-reviewed presentations and national and international invited lectureships. Dr. Dissanaike holds multiple national leadership and quality assurance roles including Chair of the American Burn Association Verification Committee, member of the American College of Surgeons Trauma Verification Committee and Committee on Trauma, and Board member of each of the American Burn Association and Southwestern Surgical Congress. She serves the American College of Surgeons as Governor and on the Committee for Ethics, the Advisory Council of Rural Surgery and Program Committee, highlighting her wide array of interests and longstanding dedication to advancing all aspects of surgical care. Dr. Dissanaike received her medical degree from the University of Sydney, Australia and her undergraduate degree from Methodist College in Colombo, Sri Lanka. Dr. Dissanaike completed her postgraduate medical training at the University of Washington at Harborview Medical Center, the Department of Surgery at TTUHSC, the Department of Surgery at Albert Einstein College of Medicine at Beth Israel Medical Center and the Department of Medicine at Inverclyde Hospital, National Health Service.
- Thomas Cusack
-
Thomas Cusack，于2025年10月27日被任命为Heron的董事。Cusack先生在投资管理和企业融资方面拥有20多年的经验。最近，从2011年到2025年，他担任Starboard Value LP的董事总经理，这是一家总部位于纽约的投资基金，管理着约90亿美元的资产，以积极投资上市公司而闻名。在此职位上，Cusack先生在评估投资机会、制定新的运营战略以及与董事会和管理团队密切合作以改善业绩和公司治理方面发挥了核心作用。在任职Starboard Value之前，2006年至2011年，他曾在巴克莱银行资本和雷曼兄弟担任投资银行家，专注于科技、媒体和电信领域的并购。Cusack先生拥有纽约大学Leonard N. Stern商学院的金融与会计学士学位。
Thomas Cusack,was appointed as a director of Heron as of October 27, 2025. Mr. Cusack has more than 20 years of experience in investment management and corporate finance. Most recently, from 2011 to 2025, he served as a Managing Director of Starboard Value LP, a New York-based investment fund with approximately $9 billion in assets under management known for its active approach to investing in public companies. In this capacity, Mr. Cusack played a central role in evaluating investment opportunities, developing new operating strategies, and working closely with boards and management teams to improve performance and corporate governance. Prior to his tenure at Starboard Value, from 2006 to 2011, he was an investment banker at Barclays Capital and Lehman Brothers focusing on Mergers & Acquisitions within the Technology, Media, & Telecom sectors. Mr. Cusack holds a B.S. in Finance & Accounting from the Leonard N. Stern School of Business at New York University. - Thomas Cusack，于2025年10月27日被任命为Heron的董事。Cusack先生在投资管理和企业融资方面拥有20多年的经验。最近，从2011年到2025年，他担任Starboard Value LP的董事总经理，这是一家总部位于纽约的投资基金，管理着约90亿美元的资产，以积极投资上市公司而闻名。在此职位上，Cusack先生在评估投资机会、制定新的运营战略以及与董事会和管理团队密切合作以改善业绩和公司治理方面发挥了核心作用。在任职Starboard Value之前，2006年至2011年，他曾在巴克莱银行资本和雷曼兄弟担任投资银行家，专注于科技、媒体和电信领域的并购。Cusack先生拥有纽约大学Leonard N. Stern商学院的金融与会计学士学位。
- Thomas Cusack,was appointed as a director of Heron as of October 27, 2025. Mr. Cusack has more than 20 years of experience in investment management and corporate finance. Most recently, from 2011 to 2025, he served as a Managing Director of Starboard Value LP, a New York-based investment fund with approximately $9 billion in assets under management known for its active approach to investing in public companies. In this capacity, Mr. Cusack played a central role in evaluating investment opportunities, developing new operating strategies, and working closely with boards and management teams to improve performance and corporate governance. Prior to his tenure at Starboard Value, from 2006 to 2011, he was an investment banker at Barclays Capital and Lehman Brothers focusing on Mergers & Acquisitions within the Technology, Media, & Telecom sectors. Mr. Cusack holds a B.S. in Finance & Accounting from the Leonard N. Stern School of Business at New York University.
- Craig A. Johnson
-
Craig A. Johnson自2014年1月起一直担任Heron Therapeutics, Inc.的董事。他现为Mirati Therapeutics, Inc.， 这是一家生物制药公司；Adamis Pharmaceuticals 公司，这是一家制药公司；和La Jolla Pharmaceutical 公司，这是一家生物制药公司的董事。他还担任Ardea Biosciences, Inc前任董事，这是一家生物技术公司，从2008年直到公司在2012年6月被 AstraZeneca PLC 收购。除了在董事会任职外，自2012年以来他曾担任过Daisas Medical, LLC顾问，这是一家健康服务公司。从2011年至2012年，他是PURE Bioscience的首席财务官，是抗菌产品的开发商，以及2010年至2011年，他曾担任NovaDel Pharma Inc.， 高级副总裁兼首席财务官，这是一家专业制药公司。 他担任TorreyPines Therapeutics副总裁兼首席财务官，这是一家生物制药公司，从2004年直到它在2009年出售给Raptor Pharmaceuticals Corp，这是一家生物制药公司。之后从2009年至2010年任Raptor Pharmaceutical Corp全资子公司副总裁。从1994年到2004年他担任过MitoKor, Inc多个职位，包括首席财务官和运营高级副总裁，这是一家生物技术公司。1994年前，他担任几个早期科技公司高级财务的位置，并且还在 Price Waterhouse 任执业会计师。他获得Michigan-Dearborn大学会计学工商管理学士学位。
Craig A. Johnson,has served as a director of Heron since 2014. Mr. Johnson has more than 30 years of experience serving in senior financial management roles and governing corporations in the biotechnology industry. He has served as a director of Aurina Pharmaceuticals Inc. since 2024.Mr. Johnson previously served as a director of Mirati Therapeutics, Inc. from 2013 until its acquisition by Bristol Myers Squibb in 2024, and as a director of La Jolla Pharmaceutical Company from 2013 until its acquisition by Innoviva, Inc. in 2022. He served as a director of Odonate Therapeutics, Inc. from 2017 to 2022, as a director of Decipher Biosciences, Inc. from 2015 to 2018, and as a director of Adamis Pharmaceuticals Corporation from 2011 to 2014. Mr. Johnson served as a director of Ardea Biosciences, Inc. from 2008 until its acquisition by AstraZeneca PLC in 2012. He served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. from 2004 until its sale to Raptor Pharmaceuticals Corp. in 2009, and then as Vice President of a wholly owned subsidiary of Raptor Pharmaceutical Corp. from 2009 to 2010. From 1994 to 2004, Mr. Johnson held various positions at MitoKor, Inc., concluding his service as Chief Financial Officer and Senior Vice President of Operations. He practiced as a Certified Public Accountant with Price Waterhouse, and he received a B.B.A. degree in accounting from the University of Michigan-Dearborn. - Craig A. Johnson自2014年1月起一直担任Heron Therapeutics, Inc.的董事。他现为Mirati Therapeutics, Inc.， 这是一家生物制药公司；Adamis Pharmaceuticals 公司，这是一家制药公司；和La Jolla Pharmaceutical 公司，这是一家生物制药公司的董事。他还担任Ardea Biosciences, Inc前任董事，这是一家生物技术公司，从2008年直到公司在2012年6月被 AstraZeneca PLC 收购。除了在董事会任职外，自2012年以来他曾担任过Daisas Medical, LLC顾问，这是一家健康服务公司。从2011年至2012年，他是PURE Bioscience的首席财务官，是抗菌产品的开发商，以及2010年至2011年，他曾担任NovaDel Pharma Inc.， 高级副总裁兼首席财务官，这是一家专业制药公司。 他担任TorreyPines Therapeutics副总裁兼首席财务官，这是一家生物制药公司，从2004年直到它在2009年出售给Raptor Pharmaceuticals Corp，这是一家生物制药公司。之后从2009年至2010年任Raptor Pharmaceutical Corp全资子公司副总裁。从1994年到2004年他担任过MitoKor, Inc多个职位，包括首席财务官和运营高级副总裁，这是一家生物技术公司。1994年前，他担任几个早期科技公司高级财务的位置，并且还在 Price Waterhouse 任执业会计师。他获得Michigan-Dearborn大学会计学工商管理学士学位。
- Craig A. Johnson,has served as a director of Heron since 2014. Mr. Johnson has more than 30 years of experience serving in senior financial management roles and governing corporations in the biotechnology industry. He has served as a director of Aurina Pharmaceuticals Inc. since 2024.Mr. Johnson previously served as a director of Mirati Therapeutics, Inc. from 2013 until its acquisition by Bristol Myers Squibb in 2024, and as a director of La Jolla Pharmaceutical Company from 2013 until its acquisition by Innoviva, Inc. in 2022. He served as a director of Odonate Therapeutics, Inc. from 2017 to 2022, as a director of Decipher Biosciences, Inc. from 2015 to 2018, and as a director of Adamis Pharmaceuticals Corporation from 2011 to 2014. Mr. Johnson served as a director of Ardea Biosciences, Inc. from 2008 until its acquisition by AstraZeneca PLC in 2012. He served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. from 2004 until its sale to Raptor Pharmaceuticals Corp. in 2009, and then as Vice President of a wholly owned subsidiary of Raptor Pharmaceutical Corp. from 2009 to 2010. From 1994 to 2004, Mr. Johnson held various positions at MitoKor, Inc., concluding his service as Chief Financial Officer and Senior Vice President of Operations. He practiced as a Certified Public Accountant with Price Waterhouse, and he received a B.B.A. degree in accounting from the University of Michigan-Dearborn.
- Christian Waage
-
Christian Waage，2013年11月起，他担任Gossamer Bio, Inc.高级副总裁和总顾问。加入Receptos前他就职于Websense Inc.，2012年7月至2013年8月被收购担任副总裁和总顾问。加入Websense之前，2008年3月至2012年7月被收购，他担任Ardea Biosciences, Inc.的副总裁和总顾问。加入Ardea Biosciences之前， 他在DLA Piper当了10多年的律师和合伙人。他在圣地亚哥大学法学院（University of San Diego School of Law）获得法学博士学位，在加州大学圣地亚哥分校（University of California, San Diego）获得经济学学士学位。
Christian Waage,has served as a director of Heron since 2016. Mr. Waage has more than 15 years of regulatory, legal and financial transaction experience, primarily in the biotechnology industry. Mr. Waage currently serves as Executive Vice President, Technical Operations and Administration of Gossamer Bio, Inc. ("Gossamer Bio"), a publicly traded biotechnology company, and previously served as Gossamer Bio's Executive President and General Counsel from 2017 to 2024. From 2013 to 2016, Mr. Waage held various positions at Receptos, Inc., a wholly owned subsidiary of Celgene Corporation, most recently serving as Managing Director. Prior to its acquisition by Celgene Corporation in 2015, he served as Senior Vice President and General Counsel of Receptos, Inc. From 2012 through its acquisition by Vista Equity Partners Management, LLC in 2013, Mr. Waage served as Vice President, General Counsel and Corporate Secretary at Websense, Inc. From 2008 through its acquisition by AstraZeneca PLC in 2012, he served as Vice President, General Counsel and Corporate Secretary of Ardea Biosciences, Inc. Prior to 2008, Mr. Waage served as a partner at DLA Piper LLP. He received a J.D. degree from the University of San Diego School of Law and a B.A. degree in economics from the University of California, San Diego. - Christian Waage，2013年11月起，他担任Gossamer Bio, Inc.高级副总裁和总顾问。加入Receptos前他就职于Websense Inc.，2012年7月至2013年8月被收购担任副总裁和总顾问。加入Websense之前，2008年3月至2012年7月被收购，他担任Ardea Biosciences, Inc.的副总裁和总顾问。加入Ardea Biosciences之前， 他在DLA Piper当了10多年的律师和合伙人。他在圣地亚哥大学法学院（University of San Diego School of Law）获得法学博士学位，在加州大学圣地亚哥分校（University of California, San Diego）获得经济学学士学位。
- Christian Waage,has served as a director of Heron since 2016. Mr. Waage has more than 15 years of regulatory, legal and financial transaction experience, primarily in the biotechnology industry. Mr. Waage currently serves as Executive Vice President, Technical Operations and Administration of Gossamer Bio, Inc. ("Gossamer Bio"), a publicly traded biotechnology company, and previously served as Gossamer Bio's Executive President and General Counsel from 2017 to 2024. From 2013 to 2016, Mr. Waage held various positions at Receptos, Inc., a wholly owned subsidiary of Celgene Corporation, most recently serving as Managing Director. Prior to its acquisition by Celgene Corporation in 2015, he served as Senior Vice President and General Counsel of Receptos, Inc. From 2012 through its acquisition by Vista Equity Partners Management, LLC in 2013, Mr. Waage served as Vice President, General Counsel and Corporate Secretary at Websense, Inc. From 2008 through its acquisition by AstraZeneca PLC in 2012, he served as Vice President, General Counsel and Corporate Secretary of Ardea Biosciences, Inc. Prior to 2008, Mr. Waage served as a partner at DLA Piper LLP. He received a J.D. degree from the University of San Diego School of Law and a B.A. degree in economics from the University of California, San Diego.
高管简历
中英对照 | 中文 | 英文- William Forbes
William Forbes于2018年8月加入我们的董事会。福布斯博士目前担任Vivelix Pharmaceuticals，Ltd.的创始人，总裁兼首席执行官，该公司是一家临床阶段的制药公司，自2016年以来专注于胃肠道疾病。创立Vivelix公司之前，Forbes博士曾任职Salix Pharmaceuticals公司，担任首席开发官，也曾担任医疗和研发主管。在加入Salix之前，Forbes博士在多家全球制药公司从事了15年的临床开发&法规事务和临床研究。
William Forbes joined Board of Directors in Augt 2018.Dr. Forbes has served as Chief Development Officer of Heron Therapeutics, Inc. (Nasdaq: HRTX), a Nasdaq traded commercial stage biotechnology company, since June 2023. Prior to joining Heron, he served as the Chief Development Officer of Trevi Therapeutics, a clinical stage pharmaceutical company foced on serio neurologically mediated diseases, from February 2021 to September 2022. Prior to Trevi, Dr. Forbes was at Salix Pharmaceuticals as the Chief Development Officer and also Head of Medical and R&D from January 2005 to June 2015. Prior to Salix, Dr. Forbes spent 15 years in Clinical Development & Regulatory Affairs and Clinical Research at a number of global pharmaceutical companies.- William Forbes于2018年8月加入我们的董事会。福布斯博士目前担任Vivelix Pharmaceuticals，Ltd.的创始人，总裁兼首席执行官，该公司是一家临床阶段的制药公司，自2016年以来专注于胃肠道疾病。创立Vivelix公司之前，Forbes博士曾任职Salix Pharmaceuticals公司，担任首席开发官，也曾担任医疗和研发主管。在加入Salix之前，Forbes博士在多家全球制药公司从事了15年的临床开发&法规事务和临床研究。
- William Forbes joined Board of Directors in Augt 2018.Dr. Forbes has served as Chief Development Officer of Heron Therapeutics, Inc. (Nasdaq: HRTX), a Nasdaq traded commercial stage biotechnology company, since June 2023. Prior to joining Heron, he served as the Chief Development Officer of Trevi Therapeutics, a clinical stage pharmaceutical company foced on serio neurologically mediated diseases, from February 2021 to September 2022. Prior to Trevi, Dr. Forbes was at Salix Pharmaceuticals as the Chief Development Officer and also Head of Medical and R&D from January 2005 to June 2015. Prior to Salix, Dr. Forbes spent 15 years in Clinical Development & Regulatory Affairs and Clinical Research at a number of global pharmaceutical companies.
- Craig Collard
Craig Collard，自2023年2月起担任Heron董事，自2023年4月起担任首席执行官。Collard先生最近担任Veloxis Pharmaceutics A/S（现为Veloxis Pharmaceuticals Inc.，“Veloxis”）的首席执行官，之后该公司于2015年至2021年12月被Asahi Kasei Corp收购，该公司是一家专注于移植的制药公司，其主要办事处位于北卡罗来纳州卡里，并继续留在Veloxis的顾问委员会中。在加入Veloxis之前，Collard先生曾于2011年担任制药公司科纳斯通医疗公司（“Cornerstone”）的首席执行官和董事会主席，直到该公司于2014年被Chiesi Farmaceutici S.P.A.收购。Collard先生还曾于2010年至2011年担任Cornerstone的临时首席财务官，并于2008年至2011年担任其总裁。Collard先生曾于2004年至2008年担任制药公司Cornerstone BioPharma Inc.（前身为Cornerstone BioPharma Holdings，Ltd.）的创始人、总裁兼首席执行官，并担任其董事会成员。在此之前，Collard先生曾担任Carolina Pharmaceuticals，Inc.的总裁兼首席执行官，这是一家他于2003年创立的专业制药公司。Collard先生目前担任TerrAscend Corp.的董事会成员，该公司是一家位于加拿大密西沙加的北美大麻运营商，自2018年12月起任职。Collard先生此前曾于2020年5月至2022年7月担任Sierra Oncology, Inc.的董事会成员，该公司是一家总部位于加利福尼亚州圣马特奥的后期生物制药公司，被葛兰素史克公司收购。他还担任Opiant Pharmaceuticals, Inc.的董事长，该公司是加利福尼亚州圣莫尼卡的一家专业制药公司，开发治疗物质和Heron Therapeutics的疗法，自2018年10月以来，该公司一直在开发治疗疾病和药物过量的疗法，直到2023年3月1日被Indivior收购。Collard先生拥有南方理工学院（现为南方理工大学州立大学）的工学学士学位。Collard先生最初是根据公司与Rubric Capital Management LP及其某些关联公司和Velan Capital Investment Management LP及其某些关联公司于2023年2月21日就董事会组成和其他相关事项的变更（“合作协议”）签订的合作协议（“合作协议”）被任命为董事。
Craig Collard,has served as a director of Heron since February 2023 and as Chief Executive Officer since April 2023. Mr. Collard most recently served as the Chief Executive Officer of Veloxis Pharmaceutics A/S (now Veloxis Pharmaceuticals Inc., "Veloxis") before it was acquired by Asahi Kasei Corp, a transplant focused pharmaceutical company with its principal office in Cary, North Carolina, from 2015 to December 2021. Prior to joining Veloxis, Mr. Collard served as the Chief Executive Officer and the Chairman of the Board of Directors of Cornerstone Therapeutics, Inc., a pharmaceutical company ("Cornerstone"), from 2011 until it was acquired by Chiesi Farmaceutici S.p.A. ("Chiesi") in 2014. Mr. Collard also served as Cornerstone's Interim Chief Financial Officer, from 2010 to 2011, and as its President, from 2008 to 2011. Mr. Collard served as the Founder, President and Chief Executive Officer of Cornerstone BioPharma Inc. (formerly Cornerstone BioPharma Holdings, Ltd.), a pharmaceutical company, and as a member of its board of directors, from 2004 to 2008. Prior to that, Mr. Collard served as President and Chief Executive Officer of Carolina Pharmaceuticals, Inc., a specialty pharmaceutical company that he founded in 2003. Mr. Collard has served on the board of directors of TerrAscend Corp. (TSX: TSND), a North American cannabis operator based in Mississauga, Canada ("TerrAscend"), since December 2018. Mr. Collard previously served as a member of the board of directors of Sierra Oncology, Inc., a San Mateo, California-based late-stage biopharmaceutical company acquired by GlaxoSmithKline plc, from May 2020 to July 2022. He also served as Chairman of Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company in Santa Monica, California developing therapies to treat substance and Heron Therapeutics, Inc. e disorders and drug overdose since October 2018 until it was acquired by Indivior on March 1, 2023. Mr. Collard holds a B.S. degree in engineering from the Southern College of Technology (now Southern Polytechnic State University). Mr. Collard was initially appointed as a director of the Company pursuant to a Cooperation Agreement, dated as of February 21, 2023 (the ''Cooperation Agreement"), by and between the Company, Rubric Capital Management LP and certain of its affiliates and Velan Capital Investment Management LP and certain of its affiliates, regarding changes to the composition of the Board and other related matters.- Craig Collard，自2023年2月起担任Heron董事，自2023年4月起担任首席执行官。Collard先生最近担任Veloxis Pharmaceutics A/S（现为Veloxis Pharmaceuticals Inc.，“Veloxis”）的首席执行官，之后该公司于2015年至2021年12月被Asahi Kasei Corp收购，该公司是一家专注于移植的制药公司，其主要办事处位于北卡罗来纳州卡里，并继续留在Veloxis的顾问委员会中。在加入Veloxis之前，Collard先生曾于2011年担任制药公司科纳斯通医疗公司（“Cornerstone”）的首席执行官和董事会主席，直到该公司于2014年被Chiesi Farmaceutici S.P.A.收购。Collard先生还曾于2010年至2011年担任Cornerstone的临时首席财务官，并于2008年至2011年担任其总裁。Collard先生曾于2004年至2008年担任制药公司Cornerstone BioPharma Inc.（前身为Cornerstone BioPharma Holdings，Ltd.）的创始人、总裁兼首席执行官，并担任其董事会成员。在此之前，Collard先生曾担任Carolina Pharmaceuticals，Inc.的总裁兼首席执行官，这是一家他于2003年创立的专业制药公司。Collard先生目前担任TerrAscend Corp.的董事会成员，该公司是一家位于加拿大密西沙加的北美大麻运营商，自2018年12月起任职。Collard先生此前曾于2020年5月至2022年7月担任Sierra Oncology, Inc.的董事会成员，该公司是一家总部位于加利福尼亚州圣马特奥的后期生物制药公司，被葛兰素史克公司收购。他还担任Opiant Pharmaceuticals, Inc.的董事长，该公司是加利福尼亚州圣莫尼卡的一家专业制药公司，开发治疗物质和Heron Therapeutics的疗法，自2018年10月以来，该公司一直在开发治疗疾病和药物过量的疗法，直到2023年3月1日被Indivior收购。Collard先生拥有南方理工学院（现为南方理工大学州立大学）的工学学士学位。Collard先生最初是根据公司与Rubric Capital Management LP及其某些关联公司和Velan Capital Investment Management LP及其某些关联公司于2023年2月21日就董事会组成和其他相关事项的变更（“合作协议”）签订的合作协议（“合作协议”）被任命为董事。
- Craig Collard,has served as a director of Heron since February 2023 and as Chief Executive Officer since April 2023. Mr. Collard most recently served as the Chief Executive Officer of Veloxis Pharmaceutics A/S (now Veloxis Pharmaceuticals Inc., "Veloxis") before it was acquired by Asahi Kasei Corp, a transplant focused pharmaceutical company with its principal office in Cary, North Carolina, from 2015 to December 2021. Prior to joining Veloxis, Mr. Collard served as the Chief Executive Officer and the Chairman of the Board of Directors of Cornerstone Therapeutics, Inc., a pharmaceutical company ("Cornerstone"), from 2011 until it was acquired by Chiesi Farmaceutici S.p.A. ("Chiesi") in 2014. Mr. Collard also served as Cornerstone's Interim Chief Financial Officer, from 2010 to 2011, and as its President, from 2008 to 2011. Mr. Collard served as the Founder, President and Chief Executive Officer of Cornerstone BioPharma Inc. (formerly Cornerstone BioPharma Holdings, Ltd.), a pharmaceutical company, and as a member of its board of directors, from 2004 to 2008. Prior to that, Mr. Collard served as President and Chief Executive Officer of Carolina Pharmaceuticals, Inc., a specialty pharmaceutical company that he founded in 2003. Mr. Collard has served on the board of directors of TerrAscend Corp. (TSX: TSND), a North American cannabis operator based in Mississauga, Canada ("TerrAscend"), since December 2018. Mr. Collard previously served as a member of the board of directors of Sierra Oncology, Inc., a San Mateo, California-based late-stage biopharmaceutical company acquired by GlaxoSmithKline plc, from May 2020 to July 2022. He also served as Chairman of Opiant Pharmaceuticals, Inc., a specialty pharmaceutical company in Santa Monica, California developing therapies to treat substance and Heron Therapeutics, Inc. e disorders and drug overdose since October 2018 until it was acquired by Indivior on March 1, 2023. Mr. Collard holds a B.S. degree in engineering from the Southern College of Technology (now Southern Polytechnic State University). Mr. Collard was initially appointed as a director of the Company pursuant to a Cooperation Agreement, dated as of February 21, 2023 (the ''Cooperation Agreement"), by and between the Company, Rubric Capital Management LP and certain of its affiliates and Velan Capital Investment Management LP and certain of its affiliates, regarding changes to the composition of the Board and other related matters.
- Ira Duarte
Ira Duarte，2023年6月加入Heron担任执行副总裁兼首席财务官。Duarte女士为Heron带来了财务领导方面的重要经验和专长。在加入Heron之前，Duarte女士曾于2016年至2023年在Veloxis（一家完全整合的专业制药公司）担任财务领导职务，最近担任首席财务官。在此之前，Duarte女士曾于2014年至2016年担任BioDelivery Sciences，Inc.的公司财务总监，并于2009年至2014年担任Chiesi USA，Inc.的公司财务高级总监和Cornerstone的会计和财务规划总监，她是指导将Cornerstone出售给Chiesi的团队的核心成员。Duarte女士此前曾在安永全球有限公司担任过从员工到高级经理的各种职务。Duarte女士自2022年12月起担任TerrAscend董事会成员。Duarte女士是一名注册会计师（非在职），拥有佛罗里达大西洋大学会计学学士学位。
Ira Duarte,joined Heron as Executive Vice President, Chief Financial Officer in June 2023. Prior to joining Heron, Ms. Duarte served in financial leadership roles from 2016 to 2023, most recently as Chief Financial Officer, at Veloxis, a fully integrated specialty pharmaceutical company. Prior to that, Ms. Duarte served as the Corporate Controller at BioDelivery Sciences, Inc. from 2014 to 2016, and from 2009 to 2014 she was Senior Director of Corporate Finance for Chiesi USA, Inc. and Director of Accounting and Financial Planning for Cornerstone, where she was a core member of the team that guided the sale of Cornerstone to Chiesi. Ms. Duarte previously held various roles from Staff to Senior Manager at Ernst & Young Global Limited. Ms. Duarte has served on the board of directors of TerrAscend since December 2022. Ms. Duarte is a Certified Public Accountant (inactive) and holds a B.S. degree in accounting from Florida Atlantic University.- Ira Duarte，2023年6月加入Heron担任执行副总裁兼首席财务官。Duarte女士为Heron带来了财务领导方面的重要经验和专长。在加入Heron之前，Duarte女士曾于2016年至2023年在Veloxis（一家完全整合的专业制药公司）担任财务领导职务，最近担任首席财务官。在此之前，Duarte女士曾于2014年至2016年担任BioDelivery Sciences，Inc.的公司财务总监，并于2009年至2014年担任Chiesi USA，Inc.的公司财务高级总监和Cornerstone的会计和财务规划总监，她是指导将Cornerstone出售给Chiesi的团队的核心成员。Duarte女士此前曾在安永全球有限公司担任过从员工到高级经理的各种职务。Duarte女士自2022年12月起担任TerrAscend董事会成员。Duarte女士是一名注册会计师（非在职），拥有佛罗里达大西洋大学会计学学士学位。
- Ira Duarte,joined Heron as Executive Vice President, Chief Financial Officer in June 2023. Prior to joining Heron, Ms. Duarte served in financial leadership roles from 2016 to 2023, most recently as Chief Financial Officer, at Veloxis, a fully integrated specialty pharmaceutical company. Prior to that, Ms. Duarte served as the Corporate Controller at BioDelivery Sciences, Inc. from 2014 to 2016, and from 2009 to 2014 she was Senior Director of Corporate Finance for Chiesi USA, Inc. and Director of Accounting and Financial Planning for Cornerstone, where she was a core member of the team that guided the sale of Cornerstone to Chiesi. Ms. Duarte previously held various roles from Staff to Senior Manager at Ernst & Young Global Limited. Ms. Duarte has served on the board of directors of TerrAscend since December 2022. Ms. Duarte is a Certified Public Accountant (inactive) and holds a B.S. degree in accounting from Florida Atlantic University.
- Mark Hensley
Mark Hensley，自2023年6月起担任Heron Therapeutics, Inc.执行副总裁、首席开发官。福布斯博士为Heron带来了30多年的医药产品开发经验，并为跨越美国和欧洲市场不同治疗领域的14项营销批准做出了贡献。在加入Heron之前，Forbes博士于2021年至2022年期间担任Trevi Therapeutics，Inc.的首席开发官。2016年至2020年，福布斯博士担任Vivelix Pharmaceuticals，Ltd.的总裁兼首席执行官，他是该公司的创始人，负责该组织的所有战略和运营方面。在此之前，Forbes博士曾于2005年至2015年在柳药医疗公司担任首席开发官，担任医疗和研发主管。在其职业生涯的早期，福布斯博士曾在Metabasis Therapeutics，Inc.、Otsuka America Pharmaceuticals，Inc.和Glaxo，Inc.担任过多个临床研发职位。福布斯博士自2018年8月起担任临床阶段医疗器械和生物制药公司Beyond Air, Inc.（纳斯达克：XAIR）的董事会成员，并自2018年11月起担任创新专业制药公司Hallux，Inc.的董事会成员。福布斯博士在克赖顿大学获得药学博士学位，他在克赖顿心脏中心完成了心血管研究和葛兰素史克公司临床研究的研究金。
Mark Hensley,has served as Heron Therapeutics, Inc. Executive Vice President, Chief Development Officer since June 2023. Prior to joining Heron, Dr. Forbes served as the Chief Development Officer at Trevi Therapeutics, Inc. from 2021 to 2022. From 2016 to 2020, Dr. Forbes served as the President and CEO of Vivelix Pharmaceuticals, Ltd., where he was the founder and responsible for all strategic and operational aspects of the organization. Prior to that, Dr. Forbes served as the Chief Development Officer at Salix Pharmaceuticals, Inc. as the Head of Medical and R&D from 2005 to 2015. Earlier in his career, Dr. Forbes held various positions in clinical research and development at Metabasis Therapeutics, Inc., Otsuka America Pharmaceuticals, Inc., and Glaxo, Inc. Dr. Forbes has served on the board of directors of Beyond Air, Inc. (Nasdaq: XAIR), a clinical-stage medical device and biopharmaceutical company, since August 2018 and has served on the board of directors of Hallux, Inc., an innovative specialty pharmaceutical company, since November 2018. Dr. Forbes received his Doctor of Pharmacy degree from Creighton University, and he completed fellowships in cardiovascular research at Creighton Cardiac Center and in clinical research at Glaxo, Inc.- Mark Hensley，自2023年6月起担任Heron Therapeutics, Inc.执行副总裁、首席开发官。福布斯博士为Heron带来了30多年的医药产品开发经验，并为跨越美国和欧洲市场不同治疗领域的14项营销批准做出了贡献。在加入Heron之前，Forbes博士于2021年至2022年期间担任Trevi Therapeutics，Inc.的首席开发官。2016年至2020年，福布斯博士担任Vivelix Pharmaceuticals，Ltd.的总裁兼首席执行官，他是该公司的创始人，负责该组织的所有战略和运营方面。在此之前，Forbes博士曾于2005年至2015年在柳药医疗公司担任首席开发官，担任医疗和研发主管。在其职业生涯的早期，福布斯博士曾在Metabasis Therapeutics，Inc.、Otsuka America Pharmaceuticals，Inc.和Glaxo，Inc.担任过多个临床研发职位。福布斯博士自2018年8月起担任临床阶段医疗器械和生物制药公司Beyond Air, Inc.（纳斯达克：XAIR）的董事会成员，并自2018年11月起担任创新专业制药公司Hallux，Inc.的董事会成员。福布斯博士在克赖顿大学获得药学博士学位，他在克赖顿心脏中心完成了心血管研究和葛兰素史克公司临床研究的研究金。
- Mark Hensley,has served as Heron Therapeutics, Inc. Executive Vice President, Chief Development Officer since June 2023. Prior to joining Heron, Dr. Forbes served as the Chief Development Officer at Trevi Therapeutics, Inc. from 2021 to 2022. From 2016 to 2020, Dr. Forbes served as the President and CEO of Vivelix Pharmaceuticals, Ltd., where he was the founder and responsible for all strategic and operational aspects of the organization. Prior to that, Dr. Forbes served as the Chief Development Officer at Salix Pharmaceuticals, Inc. as the Head of Medical and R&D from 2005 to 2015. Earlier in his career, Dr. Forbes held various positions in clinical research and development at Metabasis Therapeutics, Inc., Otsuka America Pharmaceuticals, Inc., and Glaxo, Inc. Dr. Forbes has served on the board of directors of Beyond Air, Inc. (Nasdaq: XAIR), a clinical-stage medical device and biopharmaceutical company, since August 2018 and has served on the board of directors of Hallux, Inc., an innovative specialty pharmaceutical company, since November 2018. Dr. Forbes received his Doctor of Pharmacy degree from Creighton University, and he completed fellowships in cardiovascular research at Creighton Cardiac Center and in clinical research at Glaxo, Inc.